Purpose
The twofold aim of this study was to characterize in vivo in rats the pharmacokinetics (PK) and pharmacodynamics (PD) of L6-OH, a metabolite of lerisetron with in vitro pharmacological activity, and evaluate the extent to which L6-OH contributes to the overall effect.
Methods
The PK of L6-OH was determined directly postmetabolite i.v. dose (PK-1), and also simultaneously for L (lerisetron concentration) and for generated L6-OH after lerisetron dose (200 μg kg−1, i.v.), using Nonlinear Mixed Effects Modeling with an integrated parent–metabolite PK model (PK-2). Surrogate effect was measured by inhibition of serotonin-induced bradycardia. Protein binding was assayed via ultrafiltration and all quantification was performed via liquid chromatography-electrospray ionization-mass spectrometry.
Results
L6-OH showed elevated plasma and renal clearances, and volume of distribution (PK-1). The in vivo potency (PD) of L6-OH was high (EC50 = 0.098 ng mL−1 and EC50unbound = 0.040 ng mL−1). Total clearance for L (PK-2) in the presence of generated L6-OH (CLL = CL→L6-OH + CLn) was 0.0139 L min−1. Most of this clearance was L6-OH formation (Fc = 99.6%), but only an 8.6% fraction of L6-OH was released into the bloodstream. The remainder undergoes biliar and fecal elimination. The parameters estimated from PK-2 were used to predict concentrations of L6-OH (CpL6) generated after a lerisetron therapeutic dose (10 μg kg−1) in the rat. These concentrations are needed for the PD model and are below the quantification limit. CpL6max was less than the EC50 of L6-OH.
Conclusions
We conclude that after lerisetron administration, L6-OH is extensively formed in the rat but it is quickly eliminated; therefore, besides being equipotent with the parent drug, the L6-OH metabolite does not influence the effect of lerisetron.
Similar content being viewed by others
References
P. J. Hesketh (2000) ArticleTitleComparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting Cancer Invest. 18 163–173 Occurrence Handle10705879
S. Goodin R. Cunningham (2002) ArticleTitle5-HT3-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile The Oncologist 7 424–436 Occurrence Handle10.1634/theoncologist.7-5-424 Occurrence Handle12401905
R. E. Gregory D. S. Ettinger (1998) ArticleTitle5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy Drugs 55 173–189 Occurrence Handle9506240
Y. E. Yarker D. G. McTavish (1994) ArticleTitleGranisetron: An update of its therapeutic use in nausea and vomiting induced by antineoplastic therapy Drugs 48 761–793 Occurrence Handle7530631
V. Fischer J. P. Baldeck F. L. S. Tse (1992) ArticleTitlePharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans Drug Metab. Dispos. 20 603–607 Occurrence Handle1356742
M. K. Reith G. D. Sproles L. K. Cheng (1995) ArticleTitleHuman metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist Drug Metab. Dispos. 23 806–812 Occurrence Handle7493546
N. D. Evans K. R. Godfrey M. J. Chapman M. J. Chappell L. Aarons S. B. Duffull (2001) ArticleTitleAn identifiability analysis of a parent–metabolite pharmacokinetic model for ivabradine J. Pharmacokinet. Pharmacodyn. 28 93–105 Occurrence Handle10.1023/A:1011521819898 Occurrence Handle11253617
M. Rowland T. N. Tozer (1995) Clinical Pharmacokinetics: Concepts and Applications EditionNumber3 Williams & Wilkins, Media Pennsylvania 367–393
M. Cooper A. Sologuren R. Valiente J. Smith (2002) ArticleTitleEffects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers Arzneim-Forsch./Drug Res. 52 689–694
A. Orjales R. Mosquera L. Labeaga R. Rodes (1997) ArticleTitleNew 2-piperazinylbenzimidazole derivatives as 5-HT3 antagonists. Synthesis and pharmacological evaluations J. Med. Chem. 40 586–593 Occurrence Handle10.1021/jm960442e Occurrence Handle9046349
J. R. Fozard M. Host (1982) ArticleTitleSelective inhibition of the Bezold–Jarisch effect of 5-HT in the rat by antagonists at neuronal 5-HT receptors Br. J. Pharmacol. 77 520p
M. Yamano T. Kamato A. Nishida H. Ito H. Yuki R. Tsutsumi K. Honda K. Miyata (1994) ArticleTitleSerotonin (5-HT) receptor antagonism of 4, 5, 6, 7-tetrahydrobenzimidazole derivatives against 5-HT induced bradycardia in anesthetized rats Jpn. J. Pharmacol. 65 241–248 Occurrence Handle7799524
N. Jauregizar R. Calvo E. Suárez A. Quintana E. Raczka J. C. Lukas (2001) ArticleTitleAltered disposition and effect of lerisetron in rats with elevated alpha1-acid glycoprotein levels Pharm. Res. 18 838–845 Occurrence Handle10.1023/A:1011096714860 Occurrence Handle11474789
N. Jauregizar R. Calvo E. Suarez A. Quintana E. Raczka J. C. Lukas (2002) ArticleTitlePharmacokinetics and pharmacological effect of lerisetron, a new 5-HT3 antagonist, in rats J. Pharm. Sci. 91 41–52 Occurrence Handle10.1002/jps.1169 Occurrence Handle11782896
N. Jauregizar A. Quintana E. Suarez E. Raczka L. Fuente Particlede la R. Calvo (2003) ArticleTitleAge-related changes in pharmacokinetics and pharmacodynamics of lerisetron in the rat: a population pharmacokinetic model Gerontology 49 205–214 Occurrence Handle10.1159/000070400 Occurrence Handle12792155
V. P. Shah K. K. Midha J. W. A. Findlay H. M. Hill J. D. Hulse I. J. McGilveray G. Mckay K. J. Miller R. N. Patnaik M. L. Powell A. Tonelli C. T. Viswanathan A. Yacobi (2000) ArticleTitleBioanalytical Methods validation—a revisit with a decade of progress Pharm. Res. 17 1551–1557 Occurrence Handle10.1023/A:1007669411738 Occurrence Handle11303967
R. Calvo R. M. Jimenez I. F. Troconiz E. Suarez A. Gonzalo M. L. Lucero E. Raczka A. Orjales (1998) ArticleTitleSerum protein binding of lerisetron, a novel specific 5-HT3 antagonist, in patients with cancer Cancer Chemother. Pharmacol. 42 418–422 Occurrence Handle10.1007/s002800050839 Occurrence Handle9771958
L. B. Sheiner S. L. Beal (1981) ArticleTitleSome suggestions for measuring predictive performance J. Pharmacokinet. Biopharm. 9 503–512 Occurrence Handle10.1007/BF01060893 Occurrence Handle7310648
K. P. Zuideveld J. Rusiç-Pavletiç H. J. Maas L. A. Peletier P. H. Der Graaf ParticleVan Der M. Danhof (2002) ArticleTitlePharmacokinetic–pharmacodynamic modeling of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in rats J. Pharmacol. Exp. Ther. 303 1130–1137 Occurrence Handle10.1124/jpet.102.036798 Occurrence Handle12438536
D. K. Walker (2004) ArticleTitleThe use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug development Br. J. Clin. Pharmacol. 58 601–608 Occurrence Handle10.1111/j.1365-2125.2004.02194.x Occurrence Handle15563358
D. A. Saynor C. M. Dixon (1989) ArticleTitleThe metabolism of ondansetron Eur. J. Clin. Oncol. 25 IssueIDSuppl 1 S75–S77
C. M. Dixon P. V. Colthup C. J. Serabjit-Singh B. M. Kerr C. C. Boehlert G. R. Park M. H. Tarbit (1995) ArticleTitleMultiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans Drug Metab. Dispos. 23 1225–1230 Occurrence Handle8591723
M. T. Serafini S. Puig G. Garcia-Encina R. Farran A. Garcia-Soret T. Moragon L. Martínez (1997) ArticleTitleAbsorption, distribution and excretion of [14C]-lesopitron after single and repeated administration in rats and dogs Methods Find. Exp. Clin. Pharmacol. 19 61–72 Occurrence Handle9098842
J. H. Lin M. Yamazaki (2003) ArticleTitleRole of P-glycoprotein in pharmacokinetics. Clinical implications Clin. Pharmacokinet. 42 59–98 Occurrence Handle12489979
C. Yamamoto H. Murakami N. Koyabu H. Takanaga H. Matsuo T. Uchiumi M. Kuwano M. Naito T. Tsuruo H. Ohtani Y. Sawada (2002) ArticleTitleContribution of P-glycoprotein to efflux of ramosetron a 5-HT3 receptor antagonist, across the blood–brain barrier J. Pharm. Pharmacol. 54 1055–1063 Occurrence Handle10.1211/002235702320266208 Occurrence Handle12195819
B. Tuk M. F. Oostenbruggen ParticleVan V. M. M. Herben J. W. Mandema M. Danhof (1999) ArticleTitleCharacterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: Midazolam and α-OH-midazolam J. Pharmacol. Exp. Ther. 289 1067–1074 Occurrence Handle10215689
J. Lötsch C. Skarke H. Schmidt J. Liefhold G. Geisslinger (2002) ArticleTitlePharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers Clin. Pharmacol. Ther. 72 151–162 Occurrence Handle10.1067/mcp.2002.126172 Occurrence Handle12189362
B. P. Murthy G. M. Pollack K. L. R. Brouwer (2002) ArticleTitleContribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers J. Clin. Pharmacol. 42 569–576 Occurrence Handle10.1177/00912700222011508 Occurrence Handle12017351
S. B. Martin M. Rowland (1973) ArticleTitleDetermination of tolbutamideandmetabolites in biological fluids Anal. Lett. 6 865–876
Acknowledgments
Funding for this study was provided in part by the Ministry of Science and Technology of Spain (PROFIT 2000–2003) and the Department of Industry, Commerce and Tourism of the Basque Government (INTEK 2002), and also by a UPV group grant (9/UPV 00026-327-14593/2002). One of the authors (F.O.) was funded by a Gangoiti Foundation fellowship.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ortega, F., Quintana, A., Suárez, E. et al. Pharmacokinetic–Pharmacodynamic Modeling of the Hydroxy Lerisetron Metabolite L6-OH in Rats: An Integrated Parent–Metabolite Model. Pharm Res 22, 1769–1782 (2005). https://doi.org/10.1007/s11095-005-7750-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-005-7750-6